- Home
- STE vs BGNE Comparison
STE vs BGNE Comparison
Compare STE & BGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STE
- BGNE
- Stock Information
- Founded
- STE 1985
- BGNE 2010
- Country
- STE United States
- BGNE Cayman Islands
- Employees
- STE N/A
- BGNE N/A
- Industry
- STE Industrial Specialties
- BGNE Biotechnology: Pharmaceutical Preparations
- Sector
- STE Health Care
- BGNE Health Care
- Exchange
- STE Nasdaq
- BGNE Nasdaq
- Market Cap
- STE 22.1B
- BGNE 21.0B
- IPO Year
- STE 1992
- BGNE 2016
- Fundamental
- Price
- STE $214.26
- BGNE $190.51
- Analyst Decision
- STE Buy
- BGNE Buy
- Analyst Count
- STE 6
- BGNE 7
- Target Price
- STE $253.00
- BGNE $247.07
- AVG Volume (30 Days)
- STE 732.4K
- BGNE 313.2K
- Earning Date
- STE 11-06-2024
- BGNE 11-12-2024
- Dividend Yield
- STE 1.06%
- BGNE N/A
- EPS Growth
- STE N/A
- BGNE N/A
- EPS
- STE 4.37
- BGNE N/A
- Revenue
- STE $5,325,525,000.00
- BGNE $3,351,304,621.00
- Revenue This Year
- STE $8.04
- BGNE $969.39
- Revenue Next Year
- STE $6.32
- BGNE $24.79
- P/E Ratio
- STE $36.02
- BGNE N/A
- Revenue Growth
- STE 15.75
- BGNE 50.22
- 52 Week Low
- STE $195.47
- BGNE $126.97
- 52 Week High
- STE $248.24
- BGNE $248.16
- Technical
- Relative Strength Index (RSI)
- STE 37.71
- BGNE 36.79
- Support Level
- STE $208.95
- BGNE $184.49
- Resistance Level
- STE $224.09
- BGNE $198.48
- Average True Range (ATR)
- STE 5.37
- BGNE 5.94
- MACD
- STE -0.52
- BGNE -0.65
- Stochastic Oscillator
- STE 20.39
- BGNE 23.61
About STE STERIS plc (Ireland)
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
About BGNE BeiGene Ltd.
BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene's key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.